Meta Biomed Reports Q1 2026 Operating Margin of 19.9%... Buys Back and Retires 922,856 Shares, Increases Dividend

Q1 2026 consolidated revenue: KRW 24.42bn (↓11.8% YoY), operating profit: KRW 4.85bn (↓13.6% YoY, ↑88.1% QoQ), net profit: KRW 4.39bn (↓22.2% YoY)
Operating margin of 19.9% achieved, profitability improved due to higher proportion of high-value-added products
Completed cancellation of 922,856 treasury shares (approx. KRW 2.7bn), total outstanding shares reduced to 27,171,445
27th term dividend of KRW 105 per share (↑250% vs. previous KRW 30), total dividend of KRW 2.84bn
Debt ratio at 48.4% stable, cash and cash equivalents of KRW 16.9bn
Consolidated operating cash flow of KRW 1.34bn (down from KRW 3.77bn in prior quarter)
Derivative valuation loss of KRW 1.12bn recognized, convertible bond balance of KRW 3.39bn